Home › Compare › EQRXW vs EQR

EQRXW vs EQR: Dividend Comparison 2026

EQRXW yields 4395.60% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQRXW wins by $17844003331690.00M in total portfolio value
10 years
EQRXW
EQRXW
● Live price
4395.60%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17844003331690.04M
Annual income
$17,079,643,292,413,290,000.00
Full EQRXW calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — EQRXW vs EQR

📍 EQRXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEQRXWEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EQRXW + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EQRXW pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EQRXW
Annual income on $10K today (after 15% tax)
$373,626.37/yr
After 10yr DRIP, annual income (after tax)
$14,517,696,798,551,296,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQRXW beats the other by $14,517,696,798,551,292,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EQRXW + EQR for your $10,000?

EQRXW: 50%EQR: 50%
100% EQR50/50100% EQRXW
Portfolio after 10yr
$8922001665845.04M
Annual income
$8,539,821,646,206,647,000.00/yr
Blended yield
95.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

EQRXW
No analyst data
Altman Z
9.5
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EQRXW buys
0
EQR buys
0
No recent congressional trades found for EQRXW or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEQRXWEQR
Forward yield4395.60% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$17844003331690.04M ✓$40.5K
Annual income after 10y$17,079,643,292,413,290,000.00 ✓$3,819.61
Total dividends collected$17792054110403.60M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EQRXW vs EQR ($10,000, DRIP)

YearEQRXW PortfolioEQRXW Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$450,260$439,560.44$11,248$547.57+$439.0K → EQRXW
2$18,978,664$18,496,885.68$12,701$666.53+$18.97M → EQRXW
3$748,953,345$728,646,173.66$14,405$814.59+$748.94M → EQRXW
4$27,674,743,815$26,873,363,736.79$16,413$999.84+$27674.73M → EQRXW
5$957,652,835,286$928,040,859,403.20$18,795$1,232.92+$957652.82M → EQRXW
6$31,037,578,041,538$30,012,889,507,782.54$21,639$1,527.95+$31037578.02M → EQRXW
7$942,293,671,101,243$909,083,462,596,797.50$25,057$1,903.80+$942293671.08M → EQRXW
8$26,802,238,424,024,828$25,793,984,195,946,500.00$29,197$2,385.87+$26802238424.00M → EQRXW
9$714,355,176,894,161,700$685,676,781,780,455,000.00$34,250$3,008.70+$714355176894.13M → EQRXW
10$17,844,003,331,690,041,000$17,079,643,292,413,290,000.00$40,467$3,819.61+$17844003331690.00M → EQRXW

EQRXW vs EQR: Complete Analysis 2026

EQRXW — Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. Its product pipeline in development includes Aumolertinib, an EGFR inhibitor for the treatment of ?EGFR-mutated? non-small cell lung cancer (NSCLC); Sugemalimab, an anti-PD-L1 antibody for the treatment of ?stage III and IV ?NSCLC; Lerociclib, a CDK4/6 inhibitor to treat HR+/HER2- breast cancer; and EQ176, an anti-PD-1?antibody for the treatment of liver cancer. The company has partnerships with Exscientia and AbCellera Biologics Inc. EQRx, Inc. was founded in 2020 and is based in Cambridge, Massachusetts.

Full EQRXW Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this EQRXW vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EQRXW vs SCHDEQRXW vs JEPIEQRXW vs OEQRXW vs KOEQRXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.